A trial septal defect (ASD) is a common congenital defect (1 in 1000 live births) and accounts for up to 40% of clinically relevant acyanotic shunts in adults. 1 Patent foramen ovale (PFO) is much more common and is present in more than 25% of adults. 2, 3 The clinical syndromes associated with ASD/PFO represent a significant health burden. Surgical closure is the most common therapy for these defects, and it is associated with low morbidity and mortality. However, it remains a surgical procedure requiring cardiopulmonary bypass, a significant postoperative recovery, and a sternotomy scar that may be undesirable to young patients.
Catheter-based techniques for the treatment of ASD/PFO were pioneered by King and Mills in 1975 . 4 Since then, significant device development and modifications have been made (Table 1) . Percutaneous therapy is now the preferred strategy for ASD/PFO closure, by patients and physicians alike, in the absence of complicated anatomy or another indication for traditional cardiac surgery, because it is technically simple and associated with negligible morbidity and mortality. 5 Longer-term follow-up, however, remains necessary to more completely evaluate the safety and efficacy of such devices.
The role of 2-dimensional (2D) transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) during the assessment and management of ASD/PFO has been demonstrated. 6 -8 Although universal practice standards, in the form of consensus committee guidelines or professional society recommendations, still have to be established for the use of echocardiography in this context, it is used by a majority of groups who perform these procedures. In our institution, TTE with color Doppler and/or agitated saline contrast injection is most frequently the method used to diagnose interatrial communication. Once the diagnosis has been made and percutaneous closure is deemed clinically appropriate, a careful intraprocedural assessment of interatrial septal anatomy is performed by TEE. Specifically, in the case of PFO, accurate measurement of the length of the tunnel between the septum primum and secundum and evaluation for concomitant interatrial septal aneurysm is performed. It is our practice to guide closure device placements using TEE. The multiple roles of intraprocedural TEE include confirmation of interatrial septal anatomy, preclosure and postclosure assessment of adjacent cardiac structures, including the mitral and aortic valves, systemic and pulmonary veins, and direct visualization of device position and efficacy. After successful device placement, TTE is used at routine intervals to confirm device stability and to evaluate for residual interatrial shunting. Both intraprocedural TEE and postprocedural TTE also play an important role in identifying complications of percutaneous device closure.
In recent years, intracardiac echocardiography (ICE) has been used to guide numerous percutaneous ASD/PFO closures and is the imaging modality of choice in many centers. 9, 10 ICE is typically performed intraprocedurally using an 8 or 9F catheter, which is introduced via a second femoral venous sheath. As in TEE, 2 standardized orthogonal sections are usually used to obtain defect measurements and then to guide optimal device deployment. Most commonly, the transverse section on the aortic valve plane and the longitudinal section of the 4-chamber plane are used 11 ( Figure 1 ). The advantages of ICE are multiple. The quality of the images may be superior to TEE because the transducer is within the cardiac chambers enabling high-resolution, close-up visualization of structures; accurate assessment of the interatrial septum, position and size of the defects, adequacy of the rims, and drainage of the pulmonary veins is then possible. ICE also retains an advantage over TEE in imaging the posteroinferior portion of the interatrial septum. The use of ICE obviates the need for general anesthesia, and therefore an anesthesiologist, as well as an echocardiographer-this serves to reduce the cost of the procedure. Disadvantages of ICE include the need for insertion of a second venous sheath, the requirement for supplemental training, the expense of single-use ultrasound catheters, and potential provocation of transient atrial arrhythmias. In addition, ICE has a more limited field of view than TEE and thus is less suited for the evaluation of far-field device complications. Importantly, with single operators, it may be challenging to manipulate both the ICE catheter and the closure device at the same time. At the present time, there are insufficient data to support the exclusive use of either TEE or ICE, and selection of either is left to the discretion of the interventionalist.
Although 2D echocardiography is the most widely used technique to assess interatrial septal anatomy, it may underestimate the true dimensions or the complexity of the ASD, as the septum is neither a "flat" plane 12 nor the defect a perfect circle. Three-dimensional (3D) TTE and TEE, both real-time and with image postprocessing, have been shown to be feasible for the qualitative and quantitative assessment of ASD. 13, 14 3D provides unique views of the interatrial septum and allows en-face views of the ASD. These views clearly define the morphology of the defect, as it has been shown to change during the cardiac cycle, 15 and its relation to contiguous cardiac structures thereby providing details which cannot be attained as easily by any other imaging technique ( Figure 2 major implications in the selection of patients for device closure. The use of 2D biplane imaging, a feature of commercially available 3D imaging transducers and software, is a complementary and sometimes sufficient option to the use of 3D imaging ( Figure 3 ). The advantages of this imaging modality are a high frame rate and a superior temporal resolution. The 2 orthogonal planes provide additional information compared to 1 single imaging plane-a feature highly desired during the interventional procedure when one needs to determine whether all aspects of the closure device are well seated. Initial reports of the advantages of 3D TEE in guiding catheter interventions have recently been published. 16 -18 The echocardiographic evaluation of interatrial communications has led to a better understanding of what constitutes appropriate indications and contraindications to percutaneous closure (Table 2) . 19 -21 Technical advancements in the field of percutaneous device closure are being made at a rapid rate, and as such the technology is now more widely available. As more devices are implanted, our understanding of the benefits and the risks of these procedures continues to improve. Recently, a number of complications of percutaneous ASD/ PFO closure procedures have been reported, some at the time of intervention and some in the short-and long-term postprocedure follow-up period. Intraprocedural ICE and TEE and postprocedural TTE are useful for identifying complications of percutaneous closure. 19, [22] [23] [24] This article will review important complications of percutaneous ASD/PFO closure, with an emphasis on the role of echocardiography for their diagnosis and management. 
Complications
In a recent meta-analysis of PFO closure in 1355 patients, performed between 1998 and 2004, major complications (including death, tamponade, fatal pulmonary embolism, need for urgent surgery, and transfusion) occurred in 1.5% of patients and minor complications (including atrial arrhythmias, transient heart block, asymptomatic device thrombosis, device embolization not requiring surgery, and device arm fracture) occurred in 7.9% of patients. 25 Other minor complications such as device entrapment within a Chiari network have been reported. 26 A more accurate determination of the incidence of complications can only be made once a sufficiently long follow-up is achieved in these patients. Complications can occur at the time of the interventional procedure, early postprocedure, or late during follow-up (Table 3) .
Pericardial Tamponade
As with all percutaneous intracardiac procedures, the risk of cardiac perforation exists during ASD/PFO closure. Cardiac tamponade has been reported in approximately 0.5% to 1% of patients after ASD/PFO closure. 27, 28 With device closure of ASD or PFO, tamponade most frequently results from perforation of the left atrial appendage during anchoring of the trans-septal guide wire. Less commonly, the right atrium, right ventricle, or right/left upper pulmonary vein may be the location of perforation. 29 Device erosion through adjacent cardiac tissue, as later reviewed, is another cause of pericardial tamponade.
The identification of cardiac tamponade involves integration of clinical, hemodynamic, and echocardiographic data. Intraprocedural TEE or ICE should be used continuously throughout the procedure to monitor the sudden development of a pericardial effusion, especially during excessive manipulation of intracardiac catheters. Assessment of the pericardial space should also be a compulsory component of postprocedural TTE, usually performed at 24 hours postprocedure to confirm device positioning. 
Device Erosion
The majority of ASD/PFO closure devices become fully endothelialized within several months after deployment and thus, pose little risk of erosion or migration. Over time, important modifications to device and implantation techniques have reduced the incidence of this potentially catastrophic complication. However, perforation of the right atrial roof, left atrial roof, and the aortic root by one aspect of the device have been reported following device implantation. 30 -33 Erosions have been reported with multiple devices, including the Amplatzer Septal Occluder, the Atrial Septal Defect Occluder System, and the Angel-Wings device. 29, 30, 34, 35 Of these, rare cases of aorto-atrial fistulas have been published, but none of these cases involved structural deterioration of the actual devices. 35, 36 In comparison, atrial free-wall erosion is a more common complication. In the series reported by Amin et al, 29 a panel of physicians conducted a review of all reported cases of hemodynamic compromise post-ASD closure. Erosion after ASD closure using the Amplatzer septal occluder occurred in 28 patients over the course of 6 years. In 89% of the cases, the device-treated ASDs were located high on the septum, with insufficient antero-superior rims ( Figure  4) . Of the 28 erosions, 5 involved the left atrial roof near the aortic root, whereas 6 involved the roof of the right atrium. The authors concluded that deficient rims in vulnerable areas could increase the mobility of the device with resultant excessive friction between the device and an atrial wall. Device diameter was identified as another major issue, and oversizing (Ն1.5 times the size of the ASD) was found to increase the risk of erosion. As such, conservative sizing may result in lower erosion rates. Other studies are in accordance with these risk factors. 29, 33 Other identified risk factors were all related to the potential for abrasion of the atrial or aortic wall by the device: splaying of the atrial disks across the aortic root and extreme movement of the deployed device before release (termed the Minnesota wiggle). 29 Erosion or perforation can occur as soon as 48 hours after the procedure, but also long after device implantation, sometimes without the development of any symptoms. Of the 28 (86%) cases of erosion reported by Amin et al, 24 occurred in the first 3 months whereas the latest occurred 3 years after the initial procedure. This time span and lack of symptoms underscore the need for long-term monitoring for potential complications. Although death from such mechanical complications remains rare, the risk is estimated to be around 0.11%. 37 With the use of an Amplatzer Septal Occluder, the erosion typically occurs in the left atrial roof, likely because of the larger left atrial disk. Its nitinol wire frame makes it a relatively rigid device, facilitates its positioning, and improves its stability once implanted. The downside of this Complete intraprocedural TEE or ICE evaluation during the placement of an ASD/PFO closure device is helpful for risk assessment regarding the potential for erosion into the atrial wall or the aortic root. Careful attention should be paid to whether the device impinges on the aortic root and to whether the device contacts any portion of the atrial wall other than the interatrial septum (Figure 4) . Ideally, these observations should be performed before device deployment and communicated to the interventionist. This strategy will allow repositioning of the device while it is still attached to the delivery cable.
Device Embolization
Several reports of embolization of ASD/PFO closure devices have been published. 38 -42 This remains, however, a relatively rare complication. Among studies reporting complications from percutaneous ASD closure, 11 cases of device embolization were documented in a total of 599 patients. 26, 43, 44 Ultimate stability of the device depends on anatomic factors, including adequate superior, inferior, anterior, and posterior margins of the septum adjacent to the defect. Clinicians may be tempted to ignore a small or nonexistent anterior rim when using the newer, self-centering devices, 45, 46 as evidenced by 1 report in which up to 40% of patients with deficient anterior rims underwent percutaneous closure of their ASD with the Amplatzer closure device. 45 There are no data to support the notion that the use of self-centering devices prevents or reduces embolization. Furthermore, 2 reports have shown that an anterior margin of less than 5 mm may predispose to early and late device embolization. 29, 47 Hypermobility of the interatrial septum was hypothesized to be a risk factor for unsuccessful percutaneous device closure of ASD and PFO. 48 However, an evaluation of 69 device placements at our institution revealed no significant correlation between exaggerated septal mobility and the success of device closure of interatrial communications. 48 All 69 placements involved the Sideris closure device, however, which is no longer in use.
One of the many roles of echocardiography in guiding device closure of ASD/PFO is to ensure proper placement of the device across the interatrial septum. Identification of immediate or early device embolization is possible with the TEE or ICE probe still in position ( Figures 5A, C, D and 6 ). Postprocedure TTE ( Figure  5B ) or TEE (as necessary) allows accurate identification of device malpositioning and embolization. Unfortunately, the use of echocardiography becomes limited when the device embolizes out of the heart and beyond the abdominal aorta at the hepatic level or into the peripheral vasculature. Once the location of the embolized device has been determined, especially if it is intracardiac, percutaneous device retrieval is made easier with echocardiographic guidance.
Device Thrombosis/Endocarditis
In a recent study of 1000 consecutive patients, the incidence of device thrombosis was reported to be 2% after ASD/PFO closure. 49 Three patients had minor cerebrovascular accidents, and one experienced a transient ischemic attack. Thrombus appears to be more common with devices containing uncoated metal arms such as the CardioSEAL, StarFLEX, and PFOStar than with the polyester fabric-coated Amplatzer device or the polytetrafluoroethylene-coated Helex device. 50 Most thrombi were detected within the first month after device implantation. These "early" thrombi were usually observed on TEE or intraprocedural ICE but not on TTE (Figure 7 ). Proper compliance with antiplatelet agents is essential to prevent device thrombosis. To our knowledge, there have been no reported cases of infective endocarditis affecting an ASD/PFO closure device yet; theoretically, the risk remains as long as the device has not been endothelialized.
Follow-up TEE is clearly superior to transthoracic imaging to rule out overlying thrombus on the closure device. In cases of recurrent stroke or peripheral embolization after PFO closure, for example, TEE is indicated to evaluate device positioning, to assess for residual shunt, and to rule out thrombus adherent to either atrial disk. So far, the only established risk factor for thrombosis is the material of the device. 49 -51 Although the use of devices with uncoated metal struts has decreased recently, there remains a significant percentage of patients with such devices. Thorough follow-up of these patients appears necessary because they are at an ongoing risk of thrombus formation. Determination of echocardiographic predictors of device thrombosis remains an important area for future work.
Residual Shunt
It is not uncommon to see a residual shunt in one or more areas of the interatrial septum after attempted device closure of an ASD/PFO. Residual shunts are commonly diagnosed during routine postprocedure TTE with color Doppler echocardiography or by agitated saline contrast injection, both at rest and with the Valsalva maneuver. In our experience, complex patterns of residual shunting have been noted. Interatrial shunting may occur from around the device or from within the device. Residual right-to-left shunts, seen immediately after device closure of PFO, often disappear or decrease, as the device endothelializes. However, in a certain percentage of patients, persistent shunting (in either direction) is seen many months postprocedure. Serial echocardiographic evaluations can be used in these cases to follow the degree of shunting. Appearance of symptoms should prompt a thorough evaluation of the closure device by TEE to rule out a new or worsening shunt.
In a European multicenter trial, device implantation was attempted in 200 patients with either ASD or PFO. At 1 year after implantation, the residual shunt rate was 3% (Table 4) . 26 Such residual shunting is not considered as a complication of device closure; however, it can become clinically relevant should the shunt provide, as in the case of an ASD, significant volume overload to the right heart or recurrent embolic phenomena. Membrane perforation of the ASD Occluder System, with severe left-to-right shunting, 8 years after closure has been reported in 1 case recently. 52 Clearly, this is an extremely rare complication, and this specific type of ASD occluding device has not been in use since 2000. At the present time, regular long-term follow-up is recommended in all patients with similar types of ASD occluding devices.
Conclusion
As percutaneous therapies gradually replace surgical repair of ASD/PFO, the incidence of complications of such techniques is likely to increase. Knowledge of the potential complications of device closure and their predictors will help reduce their occurrence. Complications range from minor to lifethreatening and potentially fatal. Factors involved in the incidence of complications include the interventional technique, the anatomy and size of the defect, and the type of device placed. Echocardiography has long been instrumental in the preprocedural assessment of interatrial septal anatomy. Both ICE and TEE provide complementary and necessary imaging modalities to fluoroscopy during closure device implantation. TTE and, if needed, TEE play an important role in following patients post-ASD/PFO closure device implantation. Although 2D echocardiography is a valuable tool for minimizing the occurrence of a complication, more recently developed RT3DE adds a valuable imaging perspective and supplements the information obtainable by 2D imaging. In the event of a complication, it becomes paramount to use echocardiography not only to diagnose but also to aid with therapy where appropriate. With the advent of newer imaging techniques, faster acquisition times, and improved spatial resolution, the use of echocardiography, especially as an 
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